Avadel Pharmaceuticals (AVDL) Cash & Current Investments: 2009-2022
Historic Cash & Current Investments for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to $106.5 million.
- Avadel Pharmaceuticals' Cash & Current Investments fell 41.20% to $106.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $491.3 million, marking a year-over-year decrease of 39.37%. This contributed to the annual value of $157.2 million for FY2021, which is 28.99% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Cash & Current Investments stood at $106.5 million for Q3 2022, which was up 2.26% from $104.1 million recorded in Q2 2022.
- Avadel Pharmaceuticals' Cash & Current Investments' 5-year high stood at $238.6 million during Q2 2020, with a 5-year trough of $64.2 million in Q4 2019.
- Over the past 3 years, Avadel Pharmaceuticals' median Cash & Current Investments value was $181.1 million (recorded in 2021), while the average stood at $171.4 million.
- In the last 5 years, Avadel Pharmaceuticals' Cash & Current Investments tumbled by 59.71% in 2019 and then soared by 245.09% in 2020.
- Over the past 5 years, Avadel Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $99.9 million in 2018, then plummeted by 35.79% to $64.2 million in 2019, then surged by 245.09% to $221.4 million in 2020, then fell by 28.99% to $157.2 million in 2021, then crashed by 41.20% to $106.5 million in 2022.
- Its Cash & Current Investments was $106.5 million in Q3 2022, compared to $104.1 million in Q2 2022 and $123.5 million in Q1 2022.